Laekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill

Like
Comment
Favorite

Laekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill

MT Newswires Live2024-11-28

Laekna (HKG:2105) commenced its investigational new drug-enabling study for its LAE123 drug, according to a Thursday filing with the Hong Kong Exchange.

LAE123 inhibits activin type II receptors or ActRIIA/IIB and helps prevent sarcopenia or muscle weakness.

The company has advanced the drug to pre-clinical candidate declaration, the filing said.

Price (HKD): $15.04, Change: $-0.22, Percent Change: -1.44%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2486339400?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-28 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486339400","market":"fut","top_or_hot":-1,"title":"Laekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill","media":"MT Newswires Live","content":"<html><body><p> Laekna (HKG:2105) commenced its investigational new drug-enabling study for its LAE123 drug, according to a Thursday filing with the Hong Kong Exchange.</p><p>LAE123 inhibits activin type II receptors or ActRIIA/IIB and helps prevent sarcopenia or muscle weakness.</p><p>The company has advanced the drug to pre-clinical candidate declaration, the filing said.</p><p>Price (HKD): $15.04, Change: $-0.22, Percent Change: -1.44%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Laekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLaekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-28 10:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Laekna (HKG:2105) commenced its investigational new drug-enabling study for its LAE123 drug, according to a Thursday filing with the Hong Kong Exchange.</p><p>LAE123 inhibits activin type II receptors or ActRIIA/IIB and helps prevent sarcopenia or muscle weakness.</p><p>The company has advanced the drug to pre-clinical candidate declaration, the filing said.</p><p>Price (HKD): $15.04, Change: $-0.22, Percent Change: -1.44%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486339400","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486339400","pubTimestamp":1732759760,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Laekna  commenced its investigational new drug-enabling study for its LAE123 drug, according to a Thursday filing with the Hong Kong Exchange.LAE123 inhibits activin type II receptors or ActRIIA/IIB and helps prevent sarcopenia or muscle weakness.The company has advanced the drug to pre-clinical candidate declaration, the filing said.Price : $15.04, Change: $-0.22, Percent Change: -1.44%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4023":"应用软件","02105":"来凯医药-B","BK4588":"碎股","HKD":"尚乘数科","BK1161":"生物科技","BK4526":"热门中概股"},"translate_title":"Laekna开始针对肌肉无力丸的新药研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":0.9,"HKD":1},"content_text":"Laekna (HKG:2105) commenced its investigational new drug-enabling study for its LAE123 drug, according to a Thursday filing with the Hong Kong Exchange.LAE123 inhibits activin type II receptors or ActRIIA/IIB and helps prevent sarcopenia or muscle weakness.The company has advanced the drug to pre-clinical candidate declaration, the filing said.Price (HKD): $15.04, Change: $-0.22, Percent Change: -1.44%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}